|
EGFR mutation
|
Mt – (n= 163)
|
Mt + (n= 121)
|
|---|
| |
IIIB
|
IV
|
IIIB
|
IV
|
|---|
| |
(n= 19)
|
(n= 144)
|
(n= 6)
|
(n= 115)
|
|---|
| |
No.
|
%
|
No.
|
%
|
No.
|
%
|
No.
|
%
|
|---|
|
Treatment
| | | | | | | | |
|
Platinum doublet
|
4
|
3
|
114
|
70
|
2
|
2
|
54
|
45
|
|
Monotherapy
|
0
| |
30
|
18
|
0
| |
11
|
9
|
|
EGFR-TKI
|
0
| |
0
| |
0
| |
50
|
41
|
|
Chemoradiotherapy
|
15
|
9
|
0
| |
4
|
3
|
0
| |
|
Specific regimens
| | | | | | | | |
|
Cisplatin-pemetrexed
|
1
| |
24
|
15
|
1
| |
9
|
7
|
|
Carboplatin-paclitaxel
|
3
| |
52
|
32
|
0
| |
27
|
22
|
|
Carboplatin-paclitaxel+ bev
|
0
| |
2
| |
0
| |
2
| |
|
Other platinum doublets
|
0
| |
36
|
22
|
1
| |
12
|
10
|
|
Gefitinib
|
0
| |
0
| |
0
| |
41
|
34
|
|
Erlotinib
|
0
| |
0
| |
0
| |
7
|
6
|
|
Docetaxel
|
0
| |
16
|
10
|
0
| |
3
| |
|
Vinorelbine
|
0
| |
5
| |
0
| |
2
| |
|
Others
|
0
| |
24
|
15
|
0
| |
6
| |
- Mt+: mutant EGFR, Mt-: wild-type EGFR, bev: bevacizumab.
